Equity pricing for clinical-stage biotechnology and pharmaceutical companies like Cybin—which operates under the commercial name Helus Pharma—frequently experiences sharp daily fluctuations driven by broader market sentiment, clinical trial timeline updates, cash burn rates, and macroeconomic shifts affecting high-growth risk assets. Because pre-revenue biotechnology firms rely heavily on continuous capital raises and investor enthusiasm for future drug approvals, any temporary delays in pipeline progression or shifts in sector-wide risk tolerance can trigger downward price movements. Without live internet browsing tools to inspect today's minute-by-minute trading ledger, exact intraday catalysts cannot be confirmed; however, standard daily dips typically reflect normal equity volatility or broader small-cap biotech sector pullbacks rather than isolated corporate events.